There’s a real chance you’ll need proof of a COVID-19 vaccination to enter certain venues, and Apple is hoping it can save you the hassle of digging up an email or carrying a physical card in your pocket. The company is bringing verifiable COVID-19 vaccination cards to Wallet as part of a future iPhone software update. The feature will take advantage of the international SMART Health Cards standard (already in use in several states) to produce proof of vaccination, sign it with a private key and create a public key to verify your info.

The just-released iOS 15 already lets you store verifiable vaccination and test results in the Health app using the same standard. You’ll receive your records through QR codes, downloadable files or healthcare providers who use Health Records on iPhone.

Apple is promising strict privacy for all your data. The company won’t have access to your imported or shared records, and all info must be encrypted and securely stored when transferred elsewhere. The tech giant also can’t see your vaccination card or how you’ve used it. You can share information with “approved” third-party apps, but only on a one-time basis.

Apple didn’t say when it might release the card update. This won’t thrill you if you’re anxious about the very concept of sharing your vaccination status with a concert venue or restaurant. However, it should at least streamline the process — important when you’re already running late for a show.

Editor’s note: This article originally appeared on Engadget.

Apple is reportedly working on ways to help detect and diagnose conditions such as depression, anxiety and cognitive decline using an iPhone. Researchers hope that analysis of data such as mobility, sleep patterns and how people type could spot behaviors associated with those conditions, according to The Wall Street Journal.

Other measurements could include facial expression analysis and heart and respiration rates. All of the processing would take place on the device, with no data sent to Apple servers.

The company is working on research projects that could lead to the development of these features. The University of California, Los Angeles, is studying stress, anxiety and depression, with Apple Watch and iPhone data for 3,000 volunteers being tracked in a study that starts this year. A pilot phase that began in 2020 recorded data from 150 participants.

Researchers will compare data captured from iPhone and Watch sensors with questionnaires participants fill out about how they feel, according to the report. They’re also said to be measuring the level of the stress hormone cortisol in participants’ hair follicles. Apple and UCLA announced the three-year study in August 2020.

Another research project is underway that may factor into this Apple project. The company and pharmaceutical firm Biogen said in January they’re working on a two-year study to monitor cognitive function and perhaps spot mild cognitive impairment, which has the potential to develop into Alzheimer’s. The plan is to track around 20,000 participants, around half of whom have high risk of cognitive impairment.

If data from the studies lines up with symptoms of depression or anxiety, Apple could use it to create a feature that warns users if it sees signs of a mental health condition. The iPhone could prompt users to seek care, which could be important as early detection can improve quality of life in the long run.

Apple and its partners are in the early stages of this work, so it’ll likely be a few years at least before the company adds mental health monitoring features to the iPhone. There’s no guarantee the research will lead to such features at all.

Some previous studies have indicated people with certain conditions use devices differently than other folks. It’s not yet clear whether developers can build algorithms that can detect mental health conditions reliably and accurately.

Still, there’s no smoke without fire. Health has been a growing focus for Apple over the past few years, so there’s a chance features based on this research will eventually emerge.

Editor’s note: This article originally appeared on Engadget.

BioNTech’s founding story dates back to the late 1990s, when CEO and co-founder Uğur Şahin, his wife and co-founder Özlem Türeci, and the rest of the seven-person founding team began their research.

Focused specifically on an area dubbed “New Technologies,” mRNA stood out as one area with tremendous potential to deliver the team’s ultimate goal: Developing treatments personalized to an individual and their specific ailments, rather than the traditional approach of finding a solution that happens to work generally at the population level.

Şahin, along with Mayfield venture partner Ursheet Parikh, joined us at TechCrunch Disrupt 2021 to discuss the COVID-19 vaccine, his long journey as a founder, what it takes to build a biotech platform company, and what’s coming next from BioNTech and the technologies it’s developing to help prevent other outbreaks and treat today’s deadliest diseases.

“At that time, mRNA was not potent enough,” Şahin recalled. “It was just a weak molecule. But the idea was great, so we invested many years in an academic setting to improve that. And in 2006, we realized ‘Wow, this is now working. Okay, it’s time to initiate a company’.”

Doccla, a healthtech startup with a platform that can monitor patients on hospital wards and in the home, has secured a $3.3 million Seed funding round, led by Giant Ventures and Speedinvest. The company allows hospitals to predict when beds will be freed up by monitoring patients remotely via wearable medical devices, thus helping to alleviate bottlenecks in the system.

Founded by health entrepreneur, Martin Ratz, and tech entrepreneur, Dag Larrson, Doccla says it has saved “thousands of bed days for the NHS,” achieving a 29% reduction in Emergency Admissions and a 20% reduction in A&E attendance, the company claimed.

Doccla is similar to competitors Current Health, Huma and Cadence. The latter recently raised $41 million in funding from Thrive and General Catalyst. The company offers a remote patient monitoring platform that enables clinicians to monitor patients at home and provide personalized feedback via texts and ‘video visits’. Doccla says it can also measure patients at home.

The cash raised will be used to invest in its technology, and integrate further with the medical wearables and journal record systems. It also plans to expand into European healthcare markets.
 
Once again, as we have seen with other technologies, Doccla’s development was propelled by the pandemic. It turned out that overwhelmed hospitals needed technologies like this to create ‘virtual wards’ in order to monitor patients’ journey both in the hospital and when they got home.

Dag Larsson, CEO and co-founder of Doccla said. “Our end-to-end virtual ward services are extremely easy for the care provider to take on and extremely hard for them to ignore. The NHS now faces a challenging winter season and we’re evolving our technology to support care providers.”

He added: “We differ a lot from the competition in that we support the entire patient journey (e.g all last-mile activities like logistics, customer service, and even pre-configured mobile phones). This has made us punch substantially over our weight and win contracts with extremely high patient and clinician approval.”

Cameron McLain, Managing Partner & Co-Founder from Giant Ventures added: “Doccla provides a vital solution for a strained healthcare system, delivering a product that improves the patient experience and tackles cost.”

Felix Faltin, Principal and Digital Health Lead at Speedinvest said “Doccla’s platform is more than a product, it’s a full-stack solution that makes care delivery more efficient for providers, cheaper for payors and safer for patients, long past COVID-19.”

Bringing order and understanding to unstructured information located across disparate silos has been one of more significant breakthroughs of the big data era, and today a European startup that has built a platform to help with this challenge specifically in the area of life sciences — and has, notably, been used by labs to sequence and so far identify two major Covid-19 variants — is announcing some funding to continue building out its tools to a wider set of use cases, and to expand into North America.

Seqera Labs, a Barcelona-based data orchestration and workflow platform tailored to help scientists and engineers order and gain insights from cloud-based genomic data troves, as well as to tackle other life science applications that involve harnessing complex data from multiple locations, has raised $5.5 million in seed funding.

Talis Capital and Speedinvest co-led this round, with participation also from previous backer BoxOne Ventures and a grant from the Chan Zuckerberg Initiative, Mark Zuckerberg and Dr. Priscilla Chan’s effort to back open source software projects for science applications.

Seqera — a portmanteau of “sequence” and “era”, the age of sequencing data, basically — had previously raised less than $1 million, and quietly, it is already generating revenues, with five of the world’s biggest pharmaceutical companies part of its customer base, alongside biotech and other life sciences customers.

Seqera was spun out of the Centre for Genomic Regulation, a biomedical research center based out of Barcelona, where it was built as the commercial application of Nextflow, open-source workflow and data orchestration software originally created by the founders of Seqera, Evan Floden and Paolo Di Tommaso, at the CGR.

Floden, Seqera’s CEO, told TechCrunch that he and Di Tommaso were motivated to create Seqera in 2018 after seeing Nextflow gain a lot of traction in the life science community, and subsequently getting a lot of repeat requests for further customization and features. Both Nextflow and Seqera have seen a lot of usage: the Nextflow runtime has been downloaded over 2 million times, the company said, while Seqera’s commercial cloud offering has now processed more than 5 billion tasks.

The Covid-19 pandemic is a classic example of the acute challenge that Seqera (and by association Nextflow) aims to address in the scientific community. With Covid-19 outbreaks happening globally, each time a test for Covid-19 is processed in a lab, live genetic samples of the virus get collected. Taken together, these millions of tests represent a goldmine of information about the coronavirus and how it is mutating, and when and where it is doing so. For a new virus about which so little is understood and that is still persisting, that’s invaluable data.

So the problem is not if the data exists for better insights (it does); it is that it’s nearly impossible to use more legacy tools to view that data as a holistic body. It’s in too many places, and there is just too much of it, and it’s growing every day (and changing every day), which means that traditional approaches of porting data to a centralized location to run analytics on it just wouldn’t be efficient, and would cost a fortune to execute.

That is where Segera comes in. The company’s technology treats each source of data across different clouds as a salient pipeline which can be merged and analyzed as a single body, without that data ever leaving the boundaries of the infrastructure where it already exists. Customised to focus on genomic troves, scientists can then query that information for more insights. Seqera was central to the discovery of both the alpha and delta variants of the virus, and work is still ongoing as Covid-19 continues to hammer the globe.

Seqera is being used in other kinds of medical applications, such as in the realm of so-called “precision medicine.” This is emerging as a very big opportunity in complex fields like oncology: cancer mutates and behaves differently depending on many factors, including genetic differences of the patients themselves, which means that treatments are less effective if they are “one size fits all.”

Increasingly, we are seeing approaches that leverage machine learning and big data analytics to better understand individual cancers and how they develop for different populations, to subsequently create more personalized treatments, and Seqera comes into play as a way to sequence that kind of data.

This also highlights something else notable about the Seqera platform: it is used directly by the people who are analyzing the data — that is, the researchers and scientists themselves, without data specialists necessarily needing to get involved. This was a practical priority for the company, Floden told me, but nonetheless, it’s an interesting detail of how the platform is inadvertently part of that bigger trend of “no-code/low-code” software, designed to make highly technical processes usable by non-technical people.

It’s both the existing opportunity, and how Seqera might be applied in the future across other kinds of data that lives in the cloud, that makes it an interesting company, and it seems an interesting investment, too.

“Advancements in machine learning, and the proliferation of volumes and types of data, are leading to increasingly more applications of computer science in life sciences and biology,” said Kirill Tasilov, principal at Talis Capital, in a statement. “While this is incredibly exciting from a humanity perspective, it’s also skyrocketing the cost of experiments to sometimes millions of dollars per project as they become computer-heavy and complex to run. Nextflow is already a ubiquitous solution in this space and Seqera is driving those capabilities at an enterprise level – and in doing so, is bringing the entire life sciences industry into the modern age. We’re thrilled to be a part of Seqera’s journey.”

“With the explosion of biological data from cheap, commercial DNA sequencing, there is a pressing need to analyse increasingly growing and complex quantities of data,” added Arnaud Bakker, principal at Speedinvest. “Seqera’s open and cloud-first framework provides an advanced tooling kit allowing organisations to scale complex deployments of data analysis and enable data-driven life sciences solutions.”

Although medicine and life sciences are perhaps Seqera’s most obvious and timely applications today, the framework originally designed for genetics and biology can be applied to are a number of other areas: AI training, image analysis and astronomy are three early use cases, Floden said. Astronomy is perhaps very apt, since it seems that the sky is the limit.

“We think we are in the century of biology,” Floden said. “It’s the center of activity and it’s becoming data-centric, and we are here to build services around that.”

Elvie, the women’s health tech pioneer behind a connected breast pump and smart pelvic floor exerciser, has topped up a Series C which it announced earlier this summer (July) — adding a further £12.7m to bring the total raised to £70 million ($97m).

The 2013-founded, UK-based startup previously raised a $42M Series B in 2019, and a $6M Series A in 2017 — when femtech startups were a lot rarer than they are now. Products designed for (and often by) women have gained a lot of momentum over this period as female-led startups have blazed a trail and shown there’s a sizeable market for femtech — leading investors to slow clock on to the opportunity too.

Analysts now project the femtech industry will become a $50 billion market by 2025.

Elvie says the Series C extension includes funds sponsored by the co-founders of Blume Equity – a PE firm that focuses on the food and health sectors – plus further capital from existing investors IPGL, Hiro Capital and Westerly Winds.

In July, when it announced the earlier ($80M) tranche of the raise, Elvie said the Series C was led by BGF and BlackRock alongside existing investors including Octopus Ventures.

The Series C will be used to drive for more growth through geographical expansion (including entering new markets) and diversifying its product portfolio to target other “key stages” in women’s lives, it said.

That means it’ll be splashing out on R&D to support product development — connected hardware that blends physical gadgetry with software still looks to be a strong focus — and also on strengthening its ops and infrastructure to prep for further scale.

Elvie sells four products at this stage: Its connected kegel trainer, and a wearable breast pump (plus two non-electric pumps).

Where the company goes next in terms of product will be an interesting one to watch.

Commenting in a statement, Tania Boler, CEO and founder, said: “Elvie is ready for the next phase of our growth. We have already revolutionized the categories we operate in, but we know that there is vast untapped potential to create better technology products and services for women in new areas.”

She added that Elvie’s goal is to create “the go-to destination for women’s health at all life stages” — selling “sophisticated, accurate and personalised solutions” to its target female consumer.

Homage, the caregiving-focused startup, has raised a $30 million Series C led by Sheares Healthcare Group, which is wholly-owned by investment firm Temasek. Other participants included new investors DG Daiwa Ventures and Sagana Capital, and returning backers East Ventures (Growth), HealthXCapital, SeedPlus, Trihill Capital and Alternate Ventures.

The new funding will be used to develop Homage’s technology, continue integrating with aged and disability care payer and provider infrastructure and speed-up its regional expansion outside Singapore through partnerships with hospitals and care providers.

The Singapore-based company’s services include home visits from caregivers, nurses, therapists and doctors; telemedicine; and services for chronic illnesses. One of the reasons Homage’s platform is able to scale up is its matching engine, which helps clients, like older adults and people living with chronic conditions, find providers who are best suited to their needs (the final matches are made by Homage’s team).

The startup says the round was oversubscribed and one of the largest fundings raised by an on-demand care platform in Southeast Asia and Oceania so far. It brings Homage’s total raised to more than $45 million.

As part of Series C, Sheares Healthcare Group chief corporate development officer Khoo Ee Ping will join Homage’s board of directors.

Homage now has a regional network of more than 6,000 pre-screened and trained care professionals. It claims that its business outside of Singapore has grown more than 600% year-over-year in 2021, and it has more than tripled revenue over the past year.

UK startup Oviva, which sells a digital support offering, including for Type 2 diabetes treatment, dispensing personalized diet and lifestyle advice via apps to allow more people to be able to access support, has closed $80 million in Series C funding — bringing its total raised to date to $115M.

The raise, which Oviva says will be used to scale up after a “fantastic year” of growth for the health tech business, is co-led by Sofina and Temasek, alongside existing investors AlbionVC, Earlybird, Eight Roads Ventures, F-Prime Capital, MTIP, plus several angels.

Underpinning that growth is the fact wealthy Western nations continue to see rising rates of obesity and other health conditions like Type 2 diabetes (which can be linked to poor diet and lack of exercise). While more attention is generally being paid to the notion of preventative — rather than reactive — healthcare, to manage the rising costs of service delivery.

Lifestyle management to help control weight and linked health conditions (like diabetes) is where Oviva comes in: It’s built a blended support offering that combines personalized care (provided by healthcare professionals) with digital tools for patients that help them do things like track what they’re eating, access support and chart their progress towards individual health goals.

It can point to 23 peer-reviewed publications to back up its approach — saying key results show an average of 6.8% weight loss at 6 months for those living with obesity; while, in its specialist programs, it says 53% of patients achieve remission of their type 2 diabetes at 12 months.

Oviva typically sells its digitally delivered support programs direct to health insurance companies (or publicly funded health services) — who then provide (or refer) the service to their customers/patients. Its programs are currently available in the UK, Germany, Switzerland and France — but expanding access is one of the goals for the Series C.

“We will expand to European markets where the health system reimburses the diet and lifestyle change we offer, especially those with specific pathways for digital reimbursement,” Oviva tells TechCrunch. “Encouragingly, more healthcare systems have been opening up specific routes for such digital reimbursement, e.g., Germany for DiGAs or Belgium just in the last months.”

So far, the startup has treated 200,000 people but the addressable market is clearly huge — not least as European populations age — with Oviva suggesting more than 300 million people live with “health challenges” that are either triggered by poor diet or can be optimised through personalised dietary changes. Moreover, it suggests, only “a small fraction” is currently being offered digital care.

To date, Oviva has built up 5,000+ partnerships with health systems, insurers and doctors as it looks to push for further scale by making its technology more accessible to a wider range of people. In the past year it says it’s “more than doubled” both people treated and revenue earned.

Its goal is for the Series C funding is to reach “millions” of people across Europe who need support because they’re suffering from poor health linked to diet and lifestyle.

As part of the scale up plan it will also be growing its team to 800 by the end of 2022, it adds.

On digital vs face-to-face care — setting aside the potential cost savings associated with digital delivery — it says studies show the “most striking outcome benefits” are around uptake and completion rates, noting: “We have consistently shown uptake rates above 70% and high completion rates of around 80%, even in groups considered harder to reach such as working age populations or minority ethnic groups. This compares to uptake and completion rates of less than 50% for most face-to-face services.”

Asked about competition, Oviva names Liva Healthcare and Second Nature as its closest competitors in the region.

“WW (formally Weight Watchers) also competes with a digital solution in some markets where they can access reimbursement,” it adds. “There are many others that try to access this group with new methods, but are not reimbursed or are wellness solutions. Noom competes as a solution for self-paying consumers in Europe, as many other apps. But, in our view, that is a separate market from the reimbursed medical one.”

As well as using the Series C funding to bolster its presence in existing markets and target and scale into new ones, Oviva says it may look to further grow the business via M&A opportunities.

“In expanding to new countries, we are open to both building new organisations from the ground up or acquiring existing businesses with a strong medical network where we see that our technology can be leveraged for better patient care and value creation,” it told us on that.

Doctor Anywhere, a startup that takes an “omnichannel” approach to healthcare, announced today it has raised $88 million SGD (about $65.7 million USD) in Series C funding. The round was led by Asia Partners, with participation from Novo Holdings, Philips and OSK-SBI Partners. It also included returning investors EDBI, Square Peg, IHH Healthcare, Kamet Capital and Pavilion Capital. 

As part of the round, Asia Partners co-founder Oliver Rippel and Novo Holdings Equity Asia senior partner Dr. Amit Kakar will join Doctor Anywhere’s board of directors. The company’s Series C, which it claims is one of the largest private rounds raised by a Southeast Asian healthtech company, brings its total funding to more than $140 million SGD. 

Doctor Anywhere’s omnichannel approach means that in addition to online consultations, it runs in-person clinics, provides home visits, medication deliveries and operates an in-app marketplace for health and wellness products. 

Founded in 2017 by Lim Wai Mun, Doctor Anywhere claims it now serves more than 1.5 million users. It is available in Singapore, Malaysia, Thailand, Vietnam and the Philippines, and recently established tech hubs in Bangalore and Ho Chi Minh City. 

Lim told TechCrunch in an email that when he started working on Doctor Anywhere, there were already successful telemedicine platforms in the United States, the United Kingdom and China, but the model was still nascent in Southeast Asia. A former investor, Lim began Doctor Anywhere as a side project because he had older relatives who could not leave their homes for medical visits. 

Doctor Anywhere launched as an online-only telehealth platform, but “we quickly realized that physical presence is very important in order to build trust with users,” Lim said. As a result, the company started its home care services and physical clinics. 

According to Doctor Anywhere’s estimates, the COVID-19 pandemic fast-tracked the adoption of telehealth services in Southeast Asia by at least five years. The company saw more demand for online medical consultations, medication deliveries and marketplace purchases. 

“In the past year, we have more than doubled the size of our network, from around 1,000 providers at the start of 2020 to currently close to 2,500 medical professionals across Southeast Asia,” Lim said. 

In response to the pandemic, Doctor Anywhere launched an online COVID-19 Medical Advisory Clinic last year to provide on-demand consultations for people with suspected symptoms. It also created an online mental wellness module with psychologists. Lim said the company has seen an increase in demand for mental health-related services, like insomnia and anxiety. 

Other telehealth startups in the region include WhiteCoat, Speedoc and Doctor World. Lim said Doctor Anywhere wants to differentiate by quickly launching new products in response to user inquiries, and “cultivating a balance between technology and human touch.” 

The funding will be used to deepen Doctor Anywhere’s presence in its current markets and expand into new ones. It also plans to scale its tech infrastructure and big data capabilities for a better online-to-offline user experience, and will introduce new medical specialty modules, shorten medication delivery times and develop personalized healthcare plans. 

The venture world is — quite literally — waking up to the potential of applying artificial intelligence to a wider variety of real-world, consumer-driven problems, and today comes the latest development on that front: Eight Sleep, which makes “smart” mattresses and mattress covers for regular mattresses that use machine learning and other artificial intelligence-based algorithms to improve your sleep both by changing temperature and monitoring other physical parameters to provide an overall picture of your health, has raised $86 million in a Series C round of funding.

Valor Equity Partners — the firm that has backed the likes of Tesla, SpaceX, GoPuff and many other big tech firms — is leading this latest investment, with SoftBank, Khosla Ventures, Founders Fund, and General Catalyst also participating, along with a lot of high-profile individuals who are also users for the product, athletes Alex Rodriguez, Kris Bryant and J.D. Martinez; celebs Kevin Hart; and tech figures Sophia Amorouso, Naval Ravikant and Kyle Vogt.

This Series C brings the total raised by Eight Sleep to $150 million, and the startup has confirmed to me that its valuation is now close to $500 million.

Matteo Franceschetti, Eight Sleep’s CEO, said in an interview that the funding will be used in a few ways.

First, the plan is to double down on building out more technology. Today, Eight’s Pod technology can detect your temperature, heartbeat and breathing and heat or cool a bed accordingly. Tomorrow, that could also include more physical products, additional ambient factors like lighting, and other diagnostics related to you, the sleeper.

Second, Eight Sleep wants to expand internationally, with plans to sell New York-based Eight Sleep products across Europe and the UK by the end of this year. After all, it’s not just people in the U.S. who could use a better night of sleep.

Franceschetti — who co-founded the company with Massimo Andreasi Bassi, Andrea Ballarini, and Alexandra Zatarain — told TechCrunch that he came to think about sleep and the need to improve it by way of having been an avid and active sports enthusiast.

“I was into the idea of sleep as recovery,” he said. “That is how we came up with the idea of sleep fitness.” Sleep he said, “is not just a waste of time.” Extrapolating that, it’s not just important for athletes, but everyone, to have better quality sleep.

“The vision for us is to compress your sleep and save your life,” he said. A good six hours, he added, “are better than eight hours that are not.” The company’s original name, Eight, was in reference to those fabled eight hours. Eight Sleep claims that when people use its products, they fall asleep 40% faster, get up to 20% more deep sleep, experience 30% fewer mid-night wake ups, and up to 30% fewer tosses and turns.

(But can it get me to stop worrying about Covid, the economy and societal collapse, whether my kids will be happy in life, and if we remembered to lock the door downstairs? Or maybe all of those just seem less serious when you are actually comfortable in bed…)

While Eight has definitely had a lot of traction with athletes — some 100 big names use it today — it’s hoping that the big boom in quantified self technology — hardware and software built to measure our blood pressure, heart rate, how much we sleep, how much we walk or do other activities, and much more — will mean that it can ultimately have a mass market appeal.

Indeed, we are living in a world with wearable tech that tracks our every movement is nothing new. And, as computing and communications technologies have become smaller and more portable, and infinitely more powerful, and cloud technology and advances in big data analytics has made the gathering of data and the ability to parse it more sophsiticated, we have only seen the possibilities for how that can be used to measure (and potentially “improve”) our lives increase.

Within that, sleep has been a large category of opportunity both for startups and tech companies. Earlier this year, Oura raised $100 million for its fitness and sleep tracking rings; others like Zeit have been exploring how to use wearable technology to address more acute sleep-related issues like sleep strokes.

Larger tech companies are not asleep at the wheel, either. Google recently updated its Nest Hub to track sleep; and even Apple has acquired a sleep tech company, Beddit (that deal was back in 2017, however, and it has been years since that hardware was updated: that could be one sign that Apple was more interested in using some of the technology in some of its other health-related efforts).

All this points to many more developments in a sleep tech market estimated to be worth some $30 billion. Within that Eight Sleep has been on a roll, with revenues for 2021 currently on track to triple versus 2020 on the back of two main products, a mattress that retails for $2,500 and a smart cover that sells for $1,500. (The company does not disclose user numbers but Franceschetti said that the figures are in the “several thousands,”)

2021 revenue is on track to more than triple vs. 2020. The funds will be used to accelerate the company’s innovation and technology roadmap and grow the size of the team.

“The sleep tech market is only in its infancy. The opportunity is limitless, as we spend up to a third of our lives asleep. Consumers are increasingly focused on sleep fitness as the understanding of how deeply important sleep is to overall health becomes more widely known,” said Antonio Gracias of Valor Equity in a statement.

Gracias founded Valor and is joining the board with this round, and as with other investors, he seems to have been won over in part by becoming a user: “The first night I slept on the Pod I knew we had to get involved,” he said. “We’ve seen this in our portfolio many times – Eight Sleep’s products and technology are disrupting the sleep market, and its rapid innovation is outpacing the competition as it builds a new sleep fitness focused category that delivers results.”

A lot of startup founders think there’s a dire need for their product in the market, but Liya Shuster-Bier knew for sure that there was one, because she’d required it herself prior to building it — yet nothing like it existed. Liya’s company Alula provides a new kind of shopping platform, organized based on treatment types, and includes both registry and care calendar features for helping a whole network of caregivers rally around someone’s cancer diagnosis.

On this week’s episode of Found, we talk about Liya’s entrepreneurial journey, as well as the challenges of managing a cancer diagnosis, even after remission, and how that provided her with the inspiration not just for what Alula does, but also for how the company functions. She provides us tremendous insight about what it means to be a leader, and how you can build a company that has mutual respect and concern for our shared humanity as a core value that’s also a commercial success.

We loved our time chatting with Liya, and we hope you love yours listening to the episode. And of course, we’d love if you can subscribe to Found in Apple Podcasts, on Spotify, on Google Podcasts or in your podcast app of choice. Please leave us a review and let us know what you think, or send us direct feedback either on Twitter or via email at found@techcrunch.com, or leave us a voicemail at (510) 936-1618. And please join us again next week for our next featured founder.

When it comes to climate change, it might seem that a book entitled “How to Do Nothing” would not only be irrelevant, but also downright obscene and even dangerous. Not to mention that after more than a year of pandemic living, many people are understandably fatigued at the prospect of continuing to keep their lives empty of social activities.

Yet, messing with our notions of action and contemplation is precisely the plan that Jenny Odell has laid out in her lapidary work, a meditation that is, ironically, a call to action.

Odell is a Bay Area star, who has been an artist in residence at a variety of institutions from the Internet Archive to Recology, San Francisco’s trash pickup and processing company. Her artistic work centers on attention, of focusing on the details that envelop us in this world and what we can learn from them. It’s an activity that leads her to birdwatching and long walks in Oakland’s public parks such as the Morcom Rose Garden.

Her book, it might be helpful to note, is subtitled “Resisting the Attention Economy” and Odell has made it her mission to help wean a generation, and well, a population off the spasmodic negativity that emanates from our social media platforms. In fact, she has a more ambitious goal: to wean people off the notion that productivity is the only value to life — that action is the only useful metric by which to measure ourselves. She wants to direct our attention to more important things.

“I fully understand where a life of sustained attention leads. In short, it leads to awareness,” she writes in the introduction. The key word here is sustained — and that’s also the connection with sustainability and the climate more broadly.

We don’t lack for information, data or opinions. In fact, we are overwhelmed with the dross of human thought. Some studies have shown that modern knowledge workers read more words per day than ever before in history — but they’re reading social media posts, emails, Slack messages and other ephemera that are each nibbling and collectively devouring our attention. What’s left is, for many of us, not much of any thought at all. The world is more frenetic and chaotic than ever before, but in the process, we have traded a deeper understanding of ourselves and our place in this world for an incessant deluge of media. Odell wants us to take that imbalance and level it.

For her, that means practicing a more sustained form of attention. That’s a skill most of us have little practice with (a deficit we may not even be aware of, ironically), and indeed, sustaining attention might even mean regularly refusing to engage with the world around us. That’s a good thing in her analysis. “At their loftiest, such refusals can signify the individual capacity for self-directed action against the abiding flow; at the very least, they interrupt the monotony of the everyday.”

Controlling our attention, directing it, and filtering out the noise of contemporary life results not in further atomization and narcissism, but rather a more collective sense of being. “When the pattern of your attention has changed, you render your reality differently. You begin to move and act in a different kind of world,” she writes. Suddenly, the trees and flowers that were once backdrops to our walks to brunch become complex and elegant life in their own right. We deepen our camaraderie with our friends and colleagues in ways that we never could with an emoji in Slack. We build up the potential to work together to solve problems.

Our sustained attention also allows us to notice the details of what is changing around us, the subtle variations of our environment that come from a warming planet. “Things like the American obsession with individualism, customized filter bubbles, and personal branding—anything that insists on atomized, competing individuals striving in parallel, never touching—does the same violence to human society as a dam does to a watershed.” We can’t fix what we don’t see, and with our fragmented attention, we really don’t see much.

The irony of course is that while technology products dissolve attention — building them takes an extraordinary amount of it. While some startup founders strike it rich on a whim and others are injected with product ideas from friends or VCs, the vast majority learned to sustain their attention on a market or customer for sometimes extraordinarily long periods of time in order to notice the gaps in a market. A founder recently told me that he had been working with customers in his market for more than a decade before he eventually understood a need that wasn’t being fulfilled with existing solutions.

What’s missing in the tech and startup community today is connecting that user empathy and focus on product-market fit to the attention we need in all the other aspects of our lives today. Odell analyzes it a bit more negatively than I would: we actually have these skills and in fact, use them quite specifically. We just don’t use them broadly enough to bring our minds to look at our friendships, communities and planet in a deeper light.

Doing nothing allows us to see what matters and what doesn’t. When it comes to solving big problems, particularly some of the most intractable like climate change, it’s precisely doing nothing that allows us to see the right path to doing something.

How to Do Nothing: Resisting the Attention Economy by Jenny Odell
Melville House, 2019, 256 pages

See Also

• Reader, Come Home: The Reading Brain in a Digital World by Maryanne Wolf
• Nervous States: Democracy and The Decline of Reason by William Davies
• Breaking Bread with the Dead: A Reader’s Guide to a More Tranquil Mind by Alan Jacobs